FDA approves Click’s digital therapeutic for episodic migraine

More than 37 million adults in the US are affected by migraine

The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132 as the first prescription digital therapeutic for the prevention of episodic migraine.

CT-132, which can now be prescribed for patients aged 18 years and older, is intended for adjunctive use alongside acute and/or other preventive treatments.

More than 37 million adults in the US are affected by migraine, a condition characterised by episodes of moderate-to-severe headache, nausea and increased sensitivity to light and sound.

Despite the…